找回密碼
 To register

QQ登錄

只需一步,快速開(kāi)始

掃一掃,訪問(wèn)微社區(qū)

123456
返回列表
打印 上一主題 下一主題

Titlebook: Nanoformulations in Human Health; Challenges and Appro Sushama Talegaonkar,Mahendra Rai Book 2020 Springer Nature Switzerland AG 2020 nanot

[復(fù)制鏈接]
51#
發(fā)表于 2025-3-30 11:47:45 | 只看該作者
Preformulation Challenges: The Concept Behind the Selection, Design and Preparation of Nanoformulati; strategy to improve the low entrapment efficiency and stability, etc. This chapter comprehensively summarizes all these aspects of nanoformulation development and proposes solutions for these challenges. Although a variety of nanoformulations have been described in literature, this chapter is rest
52#
發(fā)表于 2025-3-30 14:46:06 | 只看該作者
53#
發(fā)表于 2025-3-30 19:17:28 | 只看該作者
54#
發(fā)表于 2025-3-30 23:48:23 | 只看該作者
Recent Developments and Challenges in Nanoformulations Targeting Various Ailments of the Colontructure remains integrated due to minimum enzymatic activity..In recent years, the advancement in nanotechnology has tremendously helped target drugs to the colon. The nanoformulations target the drugs to the colon by using simple approaches that may be based on size, pH sensitivity, surface charge
55#
發(fā)表于 2025-3-31 03:53:42 | 只看該作者
56#
發(fā)表于 2025-3-31 07:07:15 | 只看該作者
57#
發(fā)表于 2025-3-31 11:24:35 | 只看該作者
Application of Biocompatible Nanocarriers in Glaucoma: Challenges and Advancesile, dosing frequency, systemic untoward effect, and poor patient compliance. Low drug bioavailability due to transient contact time, rapid washout by tearing, nasolacrimal drainage are some of the major issues related to the ocular pharmacotherapy. To overcome these challenges, novel biocompatible
58#
發(fā)表于 2025-3-31 14:53:01 | 只看該作者
59#
發(fā)表于 2025-3-31 18:14:40 | 只看該作者
60#
發(fā)表于 2025-3-31 23:55:28 | 只看該作者
Nanosized Labile and Particulate Ingredients in Topical Formulations: A Strategic Approach Against Pf the major cosmetic concerns and designing a broad spectrum photoprotective formulation is the need of the hour. Drugs generally used in treating skin ailments fall in the category of anti-allergic and anti-inflammatory agents, antioxidants, anti-infectives, immunosuppressants and anticancer agents
123456
返回列表
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛(ài)論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國(guó)際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-6 01:47
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
沙洋县| 高邑县| 隆子县| 易门县| 绥德县| 称多县| 阿鲁科尔沁旗| 色达县| 托克逊县| 柯坪县| 遵化市| 来安县| 康定县| 随州市| 呼和浩特市| 巴中市| 许昌市| 来宾市| 邵东县| 锡林浩特市| 涟水县| 财经| 电白县| 梁山县| 定州市| 新疆| 越西县| 绥化市| 巴里| 中方县| 河曲县| 淳化县| 吉安市| 祁连县| 福州市| 榆中县| 高平市| 贵溪市| 广东省| 锦屏县| 太湖县|